CD8A and melanoma: In 2017 Rashidian et al. used a nanobody-based tracer, 89Zr-labelled PEGylated single-domain antibody fragments specific for CD8, to track the presence of intratumoral CD8+ T-cells in the immunotherapy-susceptible B16 melanoma model in response to checkpoint blockade.